Antipsychotic
Mostrando 1-12 de 158 artigos, teses e dissertações.
-
1. Clozapine prescription trends in Brazil in the last decade
Objective: Clozapine is a second-generation antipsychotic indicated for treatment-resistant schizophrenia. Studies in several countries have shown a low rate of clozapine use despite the fact that approximately 30% of schizophrenia cases are treatment-resistant. In Brazil, few studies have addressed the frequency and variety of antipsychotic use in individua
Brazilian Journal of Psychiatry. Publicado em: 2022
-
2. Long-term effects of antipsychotics on mortality in patients with schizophrenia: a systematic review and meta-analysis
Objective: To gather current evidence on the impact of antipsychotics on long-term mortality in patients with schizophrenia. Methods: We systematically searched for articles in Embase, PubMed, and PsycINFO reporting the long-term mortality (follow-up > 1 year) of patients with schizophrenia who were using any antipsychotics. We then conducted multiple meta-
Brazilian Journal of Psychiatry. Publicado em: 2022
-
3. Health-related quality of life in patients treated with atypical antipsychotics
Objective: To assess health-related quality of life and associated factors in patients treated with atypical antipsychotics, as well as to determine utility values using the EuroQol-5D-3L instrument. Methods: A cross-sectional study was conducted at a state-run pharmacy in the Brazilian National Health System. Individuals were included if they were using a
Braz. J. Psychiatry. Publicado em: 2020-12
-
4. Acidose metabólica em pacientes com doença renal
Abstract Introduction The treatment of schizophrenia aims to reduce symptoms, improve quality of life and promote recovery from debilitating effects. Nonadherence to treatment is related to several factors and may lead to persistence of symptoms and relapse. Worldwide, the rate of nonadherence to treatment in individuals with schizophrenia is around 50%.
Braz. J. Nephrol.. Publicado em: 2020-09
-
5. Evaluation of nonadherence to treatment among patients with schizophrenia attending psychosocial care centers in the south region of Brazil
Abstract Introduction The treatment of schizophrenia aims to reduce symptoms, improve quality of life and promote recovery from debilitating effects. Nonadherence to treatment is related to several factors and may lead to persistence of symptoms and relapse. Worldwide, the rate of nonadherence to treatment in individuals with schizophrenia is around 50%.
Trends Psychiatry Psychother.. Publicado em: 2020-09
-
6. Schneider’s first-rank symptoms as predictors of remission in antipsychotic-naive first-episode psychosis
Objective: German psychiatrist Kurt Schneider proposed the concept of first-rank symptoms (FRS) of schizophrenia in 1959. However, their relevance for diagnosis and prediction of treatment response are still unclear. Most studies have investigated FRS in chronic or medicated patients. The present study sought to evaluate whether FRS predict remission, respo
Braz. J. Psychiatry. Publicado em: 2020-02
-
7. Combined influence of illness duration and medication type on visual sensitivity in schizophrenia
Objective: Patients with schizophrenia have visual processing impairments. The main findings from the literature indicate that these deficits may be related to differences in paradigms, medications, and illness duration. This study is part of a large-scale study investigating visual sensitivity in schizophrenia. Here we aimed to investigate the combined eff
Braz. J. Psychiatry. Publicado em: 2020-02
-
8. Neuroimaging of intrinsic connectivity networks: a robust method for assessing functional brain organization in psychiatric disorders
Objective: German psychiatrist Kurt Schneider proposed the concept of first-rank symptoms (FRS) of schizophrenia in 1959. However, their relevance for diagnosis and prediction of treatment response are still unclear. Most studies have investigated FRS in chronic or medicated patients. The present study sought to evaluate whether FRS predict remission, respo
Braz. J. Psychiatry. Publicado em: 2020-02
-
9. Schizophrenia: effects of aripiprazole in metabolic syndrome
Schizophrenia, in general, is characterized by severe and disabling mental alterations, characterized by the impairment of one’s mental, behavioral and social activities, developing certain clinical symptoms, relevant to the diagnosis. The drugs used for the reversion of the symptoms cause several adverse effects that affect the patient’s health and well
Braz. J. Pharm. Sci.. Publicado em: 25/11/2019
-
10. Metabolic dysregulation in early onset psychiatric disorder before and after exposure to antipsychotic drugs
Antipsychotic Drugs (APDs) are being widely prescribed to treat various disorders, including schizophrenia and bipolar disorder; however, abnormal glucose metabolism and weight gain have been reported with Atypical Anti-Psychotic drugs (AAPDs) that can lead to insulin-resistance and type 2 diabetes mellitus. The study was designed to assess various biochemic
Braz. J. Pharm. Sci.. Publicado em: 30/09/2019
-
11. CYTOTOXIC EFFECTS OF ARIPIPRAZOLE ON MKN45 AND NIH3T3 CELL LINES AND GENOTOXIC EFFECTS ON HUMAN PERIPHERAL BLOOD LYMPHOCYTES
RESUMO CONTEXTO: O câncer gástrico é conhecido como o quarto câncer mais comum. Os tratamentos atuais para o câncer danificaram os tecidos sensíveis do corpo saudável e, em muitos casos, o cancro será recorrente. Portanto, a necessidade de tratamentos que são mais eficazes é desejada. Recentemente, os pesquisadores mudaram sua atenção para os a
Arq. Gastroenterol.. Publicado em: 26/08/2019
-
12. Combined influence of illness duration and medication type on visual sensitivity in schizophrenia
Objective: Patients with schizophrenia have visual processing impairments. The main findings from the literature indicate that these deficits may be related to differences in paradigms, medications, and illness duration. This study is part of a large-scale study investigating visual sensitivity in schizophrenia. Here we aimed to investigate the combined eff
Braz. J. Psychiatry. Publicado em: 01/07/2019